Novel prenatally diagnosed compound heterozygous PXDN variants in fetal congenital primary aphakia and blepharophimosis.
Blepharophimosis
Chromosome microarray analysis (CMA)
Compound heterozygous
Congenital primary aphakia
Whole exon sequencing (WES)
Journal
Taiwanese journal of obstetrics & gynecology
ISSN: 1875-6263
Titre abrégé: Taiwan J Obstet Gynecol
Pays: China (Republic : 1949- )
ID NLM: 101213819
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
accepted:
20
07
2021
entrez:
20
5
2022
pubmed:
21
5
2022
medline:
25
5
2022
Statut:
ppublish
Résumé
To precision survey a fetal congenital primary aphakia molecular etiology. A case of 42 years old pregnancy woman prenatal diagnostic examination by amniocentesis conducted at 17 weeks' gestation and demonstrated a normal female karyotype. Trio studies based on chromosome microarray analysis (CMA) and Sanger's genetic analysis did not detect a pathologic variant of the FOXE3 gene. Fetal congenital primary aphakia accompanied with microphthalmia detected by sonography in the second trimester (22 weeks). MRI indicated bilateral absence of the lenses, consistent with primary congenital aphakia. Due to the poor prognosis of congenital aphakia, the parents decided to terminate the fetus and provided consent for an autopsy. Pathological analysis revealed dysplasia of the anterior segment of both eyes. However, post fetal mortem extended trio whole exon sequencing (WES) and Sanger's genetic analysis identified compound heterozygous variants in the chromosomal location 2p25.3 in the PXDN gene. Extended whole exon sequencing is an important tool to study primary congenital aphakia.
Identifiants
pubmed: 35595447
pii: S1028-4559(22)00087-0
doi: 10.1016/j.tjog.2022.03.019
pii:
doi:
Substances chimiques
Deoxyribonucleosides
0
Purine Nucleosides
0
5'-O-(9-phenylxanthen-9-yl)-2'-deoxynebularine
114155-96-3
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
510-513Informations de copyright
Copyright © 2022. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no conflicts of interest.